216 related articles for article (PubMed ID: 20524673)
1. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Zhang J; Jin W; Wang X; Wang J; Zhang X; Zhang Q
Mol Pharm; 2010 Aug; 7(4):1159-68. PubMed ID: 20524673
[TBL] [Abstract][Full Text] [Related]
2. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
3. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
4. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
5. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
6. Effect of ligand density and PEG modification on octreotide-targeted liposome via somatostatin receptor in vitro and in vivo.
Li H; Yuan D; Sun M; Ping Q
Drug Deliv; 2016 Nov; 23(9):3562-3572. PubMed ID: 27432585
[TBL] [Abstract][Full Text] [Related]
7. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
8. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy.
Zhang X; Yang C; Zhou J; Huo M
Small; 2016 Jul; 12(26):3578-90. PubMed ID: 27244649
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
Xiao Y; Jaskula-Sztul R; Javadi A; Xu W; Eide J; Dammalapati A; Kunnimalaiyaan M; Chen H; Gong S
Nanoscale; 2012 Nov; 4(22):7185-93. PubMed ID: 23070403
[TBL] [Abstract][Full Text] [Related]
12. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
13. iNGR-Modified Liposomes for Tumor Vascular Targeting and Tumor Tissue Penetrating Delivery in the Treatment of Glioblastoma.
Zhou JE; Yu J; Gao L; Sun L; Peng T; Wang J; Zhu J; Lu W; Zhang L; Yan Z; Yu L
Mol Pharm; 2017 May; 14(5):1811-1820. PubMed ID: 28388081
[TBL] [Abstract][Full Text] [Related]
14. Disaccharide-modified liposomes and their in vitro intracellular uptake.
Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.
Huo M; Zou A; Yao C; Zhang Y; Zhou J; Wang J; Zhu Q; Li J; Zhang Q
Biomaterials; 2012 Sep; 33(27):6393-407. PubMed ID: 22704599
[TBL] [Abstract][Full Text] [Related]
16. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
Iwase Y; Maitani Y
Mol Pharm; 2011 Apr; 8(2):330-7. PubMed ID: 21166471
[TBL] [Abstract][Full Text] [Related]
17. In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.
Zou A; Chen Y; Huo M; Wang J; Zhang Y; Zhou J; Zhang Q
J Pharm Sci; 2013 Jan; 102(1):126-35. PubMed ID: 23073894
[TBL] [Abstract][Full Text] [Related]
18. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors.
Zheng N; Dai W; Du W; Zhang H; Lei L; Zhang H; Wang X; Wang J; Zhang X; Gao J; Zhang Q
Mol Pharm; 2012 May; 9(5):1175-88. PubMed ID: 22435704
[TBL] [Abstract][Full Text] [Related]
19. Octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles as potential carriers for targeted antitumor drug delivery.
Zou A; Huo M; Zhang Y; Zhou J; Yin X; Yao C; Zhu Q; Zhang M; Ren J; Zhang Q
J Pharm Sci; 2012 Feb; 101(2):627-40. PubMed ID: 22083725
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy.
Banerjee I; De K; Mukherjee D; Dey G; Chattopadhyay S; Mukherjee M; Mandal M; Bandyopadhyay AK; Gupta A; Ganguly S; Misra M
Acta Biomater; 2016 Jul; 38():69-81. PubMed ID: 27109765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]